本帖最后由 老马 于 2012-1-13 21:20 编辑 ' ^7 r7 C9 H& z1 \: c
/ C7 t4 @' X* [
爱必妥和阿瓦斯丁的比较7 w+ u9 k# [7 [/ T6 y) F
8 {2 q" m3 e0 m, c& y! K0 khttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
: n% G1 j3 Q( ]( u% }
9 T4 W! x! x) A0 e% X. i; ]
y+ M; M3 I8 M1 q& t0 E5 y
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/: E" @% S- k4 O* `3 T4 t
==================================================
: ~+ t! _' W2 O, N7 L1 Y, b& }/ K6 nOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)9 ~& [4 q7 t8 d* v: m3 \
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. @& R$ e$ d) MResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.3 U6 U4 u5 C/ f8 W) U/ n
|